Leap Therapeutics (Leap Therapeutics) FCF Yield % : -47.92 (As of May. 22, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Leap Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Leap Therapeutics's Trailing 12-Month Free Cash Flow is $-46.57 Mil, and Market Cap is $97.19 Mil. Therefore, Leap Therapeutics's FCF Yield % for today is -47.92%.

The historical rank and industry rank for Leap Therapeutics's FCF Yield % or its related term are showing as below:

LPTX' s FCF Yield % Range Over the Past 10 Years
Min: -305.78 Med: -30.54 Max: -9.57
Current: -47.92

During the past 12 years, the highest FCF Yield % of Leap Therapeutics was -9.57%. The lowest was -305.78%. And the median was -30.54%.

LPTX's FCF Yield % is ranked worse than
75.13% of 1556 companies
in the Biotechnology industry
Industry Median: -14.16 vs LPTX: -47.92

Leap Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

Leap Therapeutics FCF Yield % Historical Data

The historical data trend for Leap Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics FCF Yield % Chart

Leap Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-99.64

-19.34

-12.29

-110.06

-41.29

Leap Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															-125.12	-50.91	-118.91	-39.18	-91.13

Competitive Comparison of Leap Therapeutics's FCF Yield %

For the Biotechnology subindustry, Leap Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Leap Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's FCF Yield % falls into.

Leap Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Leap Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-43.753	/	105.968583
	=	-41.29%

Leap Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-15.516	*	4	/	68.10531
	=	-91.13%

Leap Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Leap Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics (Leap Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (NAS:LPTX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

5MC:Germany 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.

Executives

Jason Baum	officer: Chief Scientific Officer	LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Patricia A. Martin	director	316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260
Christian M Richard	director	100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110
Richard Schilsky	director	LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Beigene, Ltd.	10 percent owner	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christine Granfield	officer: VP, Head of Reg Affairs/Qual	C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Mark O'mahony	officer: Chief Manufacturing Officer	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Cynthia Sirard	officer: Chief Medical Officer	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher Mirabelli	director, 10 percent owner, officer: CEO,Pres,Chairman of the Board	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Augustine Lawlor	10 percent owner, officer: Chief Operating Officer	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Douglas E Onsi	10 percent owner, officer: CFO,Gen Counsel,Treas, Sec.	C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Healthcare Ventures Ix, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142